DBV Technologies SA (DBVT) Receives Consensus Recommendation of “Buy” from Brokerages
Shares of DBV Technologies SA (NASDAQ:DBVT) have earned a consensus rating of “Buy” from the seven brokerages that are currently covering the company. Seven investment analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have covered the stock in the last year is $48.17.
A number of equities analysts have recently weighed in on DBVT shares. Jefferies Group set a $47.00 price target on shares of DBV Technologies SA and gave the stock a “buy” rating in a research note on Monday, October 24th. JMP Securities started coverage on shares of DBV Technologies SA in a research note on Monday, September 26th. They set an “outperform” rating and a $47.00 price target on the stock. Leerink Swann reaffirmed a “buy” rating and set a $54.00 price target on shares of DBV Technologies SA in a research note on Tuesday, August 23rd. Finally, Zacks Investment Research cut shares of DBV Technologies SA from a “hold” rating to a “sell” rating in a research note on Tuesday, September 27th.
Shares of DBV Technologies SA (NASDAQ:DBVT) traded down 2.40% during trading on Tuesday, reaching $35.74. 44,020 shares of the company’s stock were exchanged. DBV Technologies SA has a 52 week low of $22.55 and a 52 week high of $37.98. The stock has a 50 day moving average price of $35.96 and a 200-day moving average price of $34.02. The stock’s market capitalization is $1.64 billion.
Large investors have recently modified their holdings of the stock. Baker BROS. Advisors LP acquired a new stake in shares of DBV Technologies SA during the third quarter worth approximately $200,162,000. Deerfield Management Co. boosted its stake in shares of DBV Technologies SA by 113.2% in the second quarter. Deerfield Management Co. now owns 1,743,229 shares of the company’s stock worth $56,864,000 after buying an additional 925,423 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in shares of DBV Technologies SA during the third quarter worth approximately $6,114,000. Exane Asset Management acquired a new stake in shares of DBV Technologies SA during the second quarter worth approximately $4,407,000. Finally, Alliancebernstein L.P. boosted its stake in shares of DBV Technologies SA by 20.3% in the second quarter. Alliancebernstein L.P. now owns 794,220 shares of the company’s stock worth $25,907,000 after buying an additional 133,953 shares during the last quarter. 47.40% of the stock is currently owned by hedge funds and other institutional investors.
About DBV Technologies SA
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Stock Ratings for DBV Technologies SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies SA and related stocks with our FREE daily email newsletter.